We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

EMEA Issues Guidance On Biosimilar Drugs

Law360 (July 16, 2007, 12:00 AM EDT) -- In a move that is likely to spark debate on both sides of the Atlantic, the European Medical Agency has issued new guidelines on the approval and regulation of biosimilar medicines, stating that they should not be treated like generic drugs.

The guidelines, titled “Questions and Answers on Biosimilar Medicines” and published on Monday, clarifies the process by which biosimilar treatments—medicines that are derived from a living organism—are approved and regulated.

In the document, the EMEA states that “due to the differences stemming from the variability...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.